Antiepileptic Drug Therapy for Status Epilepticus

Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical neurology (Seoul, Korea) Vol. 17; no. 1; pp. 11 - 19
Main Authors Kim, Daeyoung, Kim, Jae-Moon, Cho, Yong Won, Yang, Kwang Ik, Kim, Dong Wook, Lee, Soon-Tae, No, Young Joo, Seo, Jong-Geun, Byun, Jung-Ick, Kang, Kyung Wook, Kim, Keun Tae
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Neurological Association 01.01.2021
대한신경과학회
Subjects
Review
신경과학
antiepileptic drugs
status epilepticus
benzodiazepines
drug therapy
seizure
anesthetics
Online AccessGet full text
ISSN1738-6586
2005-5013
DOI10.3988/jcn.2021.17.1.11

Cover

Abstract Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required.
AbstractList Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required.
Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required.Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required.
Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required. KCI Citation Count: 0
Author Yang, Kwang Ik
Lee, Soon-Tae
Seo, Jong-Geun
Kim, Keun Tae
Kang, Kyung Wook
Kim, Daeyoung
No, Young Joo
Byun, Jung-Ick
Kim, Dong Wook
Cho, Yong Won
Kim, Jae-Moon
AuthorAffiliation b Department of Neurology, Keimyung University School of Medicine, Daegu, Korea
g Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea
h Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, Korea
c Department of Neurology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Korea
f Department of Neurology, Samsung Noble County, Yongin, Korea
i Department of Neurology, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju, Korea
e Department of Neurology, Seoul National University Hospital, Seoul, Korea
a Department of Neurology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
d Department of Neurology, Konkuk University School of Medicine, Seoul, Korea
AuthorAffiliation_xml – name: a Department of Neurology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
– name: f Department of Neurology, Samsung Noble County, Yongin, Korea
– name: g Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea
– name: b Department of Neurology, Keimyung University School of Medicine, Daegu, Korea
– name: e Department of Neurology, Seoul National University Hospital, Seoul, Korea
– name: d Department of Neurology, Konkuk University School of Medicine, Seoul, Korea
– name: h Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, Korea
– name: i Department of Neurology, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju, Korea
– name: c Department of Neurology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Korea
Author_xml – sequence: 1
  givenname: Daeyoung
  orcidid: 0000-0001-9056-0017
  surname: Kim
  fullname: Kim, Daeyoung
  organization: Department of Neurology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
– sequence: 2
  givenname: Jae-Moon
  orcidid: 0000-0002-5035-9877
  surname: Kim
  fullname: Kim, Jae-Moon
  organization: Department of Neurology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
– sequence: 3
  givenname: Yong Won
  orcidid: 0000-0002-6127-1045
  surname: Cho
  fullname: Cho, Yong Won
  organization: Department of Neurology, Keimyung University School of Medicine, Daegu, Korea
– sequence: 4
  givenname: Kwang Ik
  orcidid: 0000-0001-6343-6520
  surname: Yang
  fullname: Yang, Kwang Ik
  organization: Department of Neurology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Korea
– sequence: 5
  givenname: Dong Wook
  orcidid: 0000-0003-4484-0602
  surname: Kim
  fullname: Kim, Dong Wook
  organization: Department of Neurology, Konkuk University School of Medicine, Seoul, Korea
– sequence: 6
  givenname: Soon-Tae
  orcidid: 0000-0003-4767-7564
  surname: Lee
  fullname: Lee, Soon-Tae
  organization: Department of Neurology, Seoul National University Hospital, Seoul, Korea
– sequence: 7
  givenname: Young Joo
  orcidid: 0000-0002-0145-5707
  surname: No
  fullname: No, Young Joo
  organization: Department of Neurology, Samsung Noble County, Yongin, Korea
– sequence: 8
  givenname: Jong-Geun
  orcidid: 0000-0002-3944-5731
  surname: Seo
  fullname: Seo, Jong-Geun
  organization: Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea
– sequence: 9
  givenname: Jung-Ick
  orcidid: 0000-0002-6224-4575
  surname: Byun
  fullname: Byun, Jung-Ick
  organization: Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, Korea
– sequence: 10
  givenname: Kyung Wook
  orcidid: 0000-0001-9362-8670
  surname: Kang
  fullname: Kang, Kyung Wook
  organization: Department of Neurology, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju, Korea
– sequence: 11
  givenname: Keun Tae
  orcidid: 0000-0002-7124-0736
  surname: Kim
  fullname: Kim, Keun Tae
  organization: Department of Neurology, Keimyung University School of Medicine, Daegu, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33480193$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002673825$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1kc1LxDAQxYMouqvePUmPeug6adImuQjL-gmCoOs5pGmi0W5bk1bwvze7q6KCl5lDfu-9MG-MNpu2MQgdYJgQwfnJs24mGWR4gtkkDryBRhlAnuaAySYaYUZ4WuS82EHjEJ4BCgYcb6MdQigHLMgI4WnTO9O52nS908mZHx6T-ZPxqntPbOuT-171Q0jOv4gh7KEtq-pg9j_3Lnq4OJ_PrtKb28vr2fQm1ZRAn9pSsEpzUSlqOYA1YGJ2roi2YGwhqrIoLa4os0BLJnTJuIVKaKNJjqkuyS46Xvs23soX7WSr3Go_tvLFy-nd_FqKgjKck8iertluKBem0qbpvapl591C-feV8vdL456iz5tknALBOBocfRr49nUwoZcLF7Spa9WYdggyi_fKmADKI3r4M-s75OumEYA1oH0bgjf2G8Egl7XJWJtc1iYxk3Es44s_Eu3i4V27_K2r_xd-ALEXnZ8
CitedBy_id crossref_primary_10_1016_j_neuarg_2023_08_001
crossref_primary_10_53365_nrfhh_192949
crossref_primary_10_1080_00397911_2025_2457439
crossref_primary_10_7759_cureus_53168
crossref_primary_10_1016_j_yebeh_2024_109921
crossref_primary_10_1007_s40290_023_00475_x
crossref_primary_10_3389_fneur_2022_821917
crossref_primary_10_4103_2221_1691_389573
crossref_primary_10_5005_jp_journals_11006_0025
crossref_primary_10_1007_s11011_022_01052_y
crossref_primary_10_1016_j_eplepsyres_2024_107360
crossref_primary_10_1007_s00415_021_10751_y
Cites_doi 10.1017/CBO9780511526930.003
10.1111/epi.12064
10.1016/j.ejpn.2009.02.004
10.1016/j.yebeh.2019.106675
10.1111/j.1528-1167.2009.02323.x
10.1093/brain/aws091
10.1111/j.1528-1157.1970.tb03871.x
10.1111/epi.13716
10.1016/j.seizure.2018.08.004
10.1007/s12028-012-9695-z
10.1001/jama.2014.2625
10.1001/jama.1983.03330350028021
10.1056/NEJMoa1905795
10.1016/j.yebeh.2015.06.032
10.1046/j.1528-1157.2002.28501.x
10.1523/JNEUROSCI.4944-04.2005
10.1111/epi.13121
10.1111/j.1528-1167.2009.02297.x
10.1097/CCM.0000000000000881
10.1038/nrneurol.2016.45
10.1093/bja/68.5.486
10.1007/s40263-018-0569-6
10.1111/epi.12058
10.1007/s40263-014-0167-1
10.1212/WNL.0b013e318278b685
10.5698/1535-7597-16.1.48
10.1111/epi.12247
10.1016/0887-8994(91)90042-J
10.1111/j.1528-1157.1981.tb06159.x
10.1212/WNL.51.4.1034
10.1111/j.1468-1331.2009.02917.x
10.1684/j.1950-6945.2005.tb00092.x
10.1111/j.1528-1167.2007.00989.x
10.1111/j.1528-1167.2011.03243.x
10.1016/j.yebeh.2019.106466
10.1586/14737175.2015.1088785
10.1212/WNL.46.6_Suppl_1.17S
10.1212/WNL.28.9.874
10.1212/WNL.46.2.465
10.1001/archneur.59.2.205
10.1016/j.seizure.2012.01.008
10.1684/j.1950-6945.2005.tb00093.x
10.14581/jer.11011
10.1212/WNL.0000000000000009
10.1111/j.1528-1167.2010.02622.x
10.1093/brain/awr215
10.7551/mitpress/6456.003.0010
10.1056/NEJM199809173391202
10.1212/WNL.0000000000000054
10.1001/jama.1983.03330300046032
10.1016/j.eplepsyres.2015.07.005
10.1001/jamaneurol.2013.578
10.1136/jnnp.2004.041947
10.20344/amp.9679
10.1111/j.1527-3458.2008.00043.x
10.1111/j.1528-1167.2007.01478.x
10.1007/s40265-015-0454-2
10.1097/CCM.0b013e3182591ff1
10.1111/j.1469-8749.1995.tb15014.x
10.1016/j.eplepsyres.2010.12.014
10.1016/S0149-2918(97)80126-9
10.1056/NEJMoa002141
10.1046/j.1528-1157.2001.10401.x
10.1007/s12028-010-9445-z
10.1016/j.seizure.2013.12.007
10.1111/j.1528-1167.2011.03237.x
10.1056/NEJMoa1107494
10.2165/00003495-198428060-00002
10.1016/j.yebeh.2018.04.025
ContentType Journal Article
Copyright Copyright © 2021 Korean Neurological Association.
Copyright © 2021 Korean Neurological Association 2021 Korean Neurological Association
Copyright_xml – notice: Copyright © 2021 Korean Neurological Association.
– notice: Copyright © 2021 Korean Neurological Association 2021 Korean Neurological Association
CorporateAuthor on behalf of the Drug Committee of Korean Epilepsy Society
Drug Committee of Korean Epilepsy Society
CorporateAuthor_xml – name: on behalf of the Drug Committee of Korean Epilepsy Society
– name: Drug Committee of Korean Epilepsy Society
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.3988/jcn.2021.17.1.11
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-5013
EndPage 19
ExternalDocumentID oai_kci_go_kr_ARTI_9647153
PMC7840311
33480193
10_3988_jcn_2021_17_1_11
Genre Journal Article
Review
GroupedDBID 29K
2WC
5-W
5GY
8JR
8XY
9ZL
AAKDD
AAYXX
ACYCR
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
D-I
DIK
DU5
E3Z
EF.
F5P
GROUPED_DOAJ
HYE
KQ8
M48
OK1
PGMZT
RPM
M~E
NPM
7X8
5PM
ID FETCH-LOGICAL-c430t-fb97dc89da4f800fe0e0815a3cf0ef69db6bf1d47f04b79cb78f0d9cec3514cb3
IEDL.DBID M48
ISSN 1738-6586
IngestDate Tue Nov 21 21:39:06 EST 2023
Thu Aug 21 14:11:18 EDT 2025
Thu Jul 10 17:00:23 EDT 2025
Thu Jan 02 22:57:31 EST 2025
Tue Jul 01 03:10:52 EDT 2025
Thu Apr 24 23:03:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords antiepileptic drugs
status epilepticus
benzodiazepines
drug therapy
seizure
anesthetics
Language English
License Copyright © 2021 Korean Neurological Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c430t-fb97dc89da4f800fe0e0815a3cf0ef69db6bf1d47f04b79cb78f0d9cec3514cb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
https://doi.org/10.3988/jcn.2021.17.1.11
ORCID 0000-0001-9056-0017
0000-0001-9362-8670
0000-0003-4767-7564
0000-0002-6224-4575
0000-0002-5035-9877
0000-0001-6343-6520
0000-0002-3944-5731
0000-0003-4484-0602
0000-0002-7124-0736
0000-0002-6127-1045
0000-0002-0145-5707
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3988/jcn.2021.17.1.11
PMID 33480193
PQID 2480279048
PQPubID 23479
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9647153
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7840311
proquest_miscellaneous_2480279048
pubmed_primary_33480193
crossref_primary_10_3988_jcn_2021_17_1_11
crossref_citationtrail_10_3988_jcn_2021_17_1_11
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of clinical neurology (Seoul, Korea)
PublicationTitleAlternate J Clin Neurol
PublicationYear 2021
Publisher Korean Neurological Association
대한신경과학회
Publisher_xml – name: Korean Neurological Association
– name: 대한신경과학회
References Cranford (10.3988/jcn.2021.17.1.11_ref32) 1978; 28
Prasad (10.3988/jcn.2021.17.1.11_ref25) 2014; 2014
Fernandez (10.3988/jcn.2021.17.1.11_ref56) 2014; 82
Kotani (10.3988/jcn.2021.17.1.11_ref58) 2008; 14
Amengual-Gual (10.3988/jcn.2021.17.1.11_ref75) 2019; 68
Greenblatt (10.3988/jcn.2021.17.1.11_ref24) 1989; 250
Gaspard (10.3988/jcn.2021.17.1.11_ref68) 2013; 54
Brophy (10.3988/jcn.2021.17.1.11_ref21) 2012; 17
Kowalski (10.3988/jcn.2021.17.1.11_ref51) 2012; 40
Appleton (10.3988/jcn.2021.17.1.11_ref15) 1995; 37
Fujikawa (10.3988/jcn.2021.17.1.11_ref71) 2006
Limdi (10.3988/jcn.2021.17.1.11_ref37) 2007; 48
Gomes (10.3988/jcn.2021.17.1.11_ref64) 2018; 31
Brigo (10.3988/jcn.2021.17.1.11_ref29) 2019; 101
Sutter (10.3988/jcn.2021.17.1.11_ref73) 2016; 12
Rosati (10.3988/jcn.2021.17.1.11_ref67) 2012; 79
Gastaut (10.3988/jcn.2021.17.1.11_ref3) 1970; 11
Ramsay (10.3988/jcn.2021.17.1.11_ref36) 1996; 46
Bauer (10.3988/jcn.2021.17.1.11_ref72) 2010; 51
Alldredge (10.3988/jcn.2021.17.1.11_ref17) 2001; 345
Leppik (10.3988/jcn.2021.17.1.11_ref14) 1983; 249
Sutter (10.3988/jcn.2021.17.1.11_ref53) 2014; 82
Clark (10.3988/jcn.2021.17.1.11_ref11) 1904; 60
Trinka (10.3988/jcn.2021.17.1.11_ref13) 2015; 75
Mayer (10.3988/jcn.2021.17.1.11_ref47) 2002; 59
Rossetti (10.3988/jcn.2021.17.1.11_ref62) 2011; 14
Chamberlain (10.3988/jcn.2021.17.1.11_ref20) 2014; 311
Yasiry (10.3988/jcn.2021.17.1.11_ref28) 2014; 23
Zelano (10.3988/jcn.2021.17.1.11_ref40) 2012; 21
Marchi (10.3988/jcn.2021.17.1.11_ref54) 2015; 43
Santamarina (10.3988/jcn.2021.17.1.11_ref45) 2018; 84
Naylor (10.3988/jcn.2021.17.1.11_ref66) 2010; 51 Suppl 3
Engel (10.3988/jcn.2021.17.1.11_ref6) 2001; 42
Wasterlain (10.3988/jcn.2021.17.1.11_ref42) 2011; 94
Höfler (10.3988/jcn.2021.17.1.11_ref43) 2013; 54
Treiman (10.3988/jcn.2021.17.1.11_ref16) 1998; 339
Dundee (10.3988/jcn.2021.17.1.11_ref27) 1984; 28
Zeiler (10.3988/jcn.2021.17.1.11_ref70) 2015; 2015
Commission on Classification and Terminology of the International League Against Epilepsy (10.3988/jcn.2021.17.1.11_ref4) 1981; 22
Minicucci (10.3988/jcn.2021.17.1.11_ref23) 2020; 102
Clark (10.3988/jcn.2021.17.1.11_ref9) 1903; 60
Sutter (10.3988/jcn.2021.17.1.11_ref50) 2013; 54
Wasterlain (10.3988/jcn.2021.17.1.11_ref76) 2011; 52 Suppl 8
Shorvon (10.3988/jcn.2021.17.1.11_ref5) 1994
Shorvon (10.3988/jcn.2021.17.1.11_ref26) 2008; 49
Clark (10.3988/jcn.2021.17.1.11_ref10) 1904; 60
Fragen (10.3988/jcn.2021.17.1.11_ref55) 1997; 19
Kim (10.3988/jcn.2021.17.1.11_ref2) 2011; 1
Meierkord (10.3988/jcn.2021.17.1.11_ref63) 2010; 17
Uysal (10.3988/jcn.2021.17.1.11_ref74) 2015; 116
Trinka (10.3988/jcn.2021.17.1.11_ref1) 2015; 56
Cock (10.3988/jcn.2021.17.1.11_ref30) 2011; 52 Suppl 8
Rona (10.3988/jcn.2021.17.1.11_ref7) 2005; 7
Bailie (10.3988/jcn.2021.17.1.11_ref57) 1992; 68
Zheng (10.3988/jcn.2021.17.1.11_ref41) 2015; 15
Claassen (10.3988/jcn.2021.17.1.11_ref61) 2002; 43
Riviello (10.3988/jcn.2021.17.1.11_ref33) 1991; 7
Hocker (10.3988/jcn.2021.17.1.11_ref52) 2013; 70
Earnest (10.3988/jcn.2021.17.1.11_ref35) 1983; 249
Ramsay (10.3988/jcn.2021.17.1.11_ref46) 2015; 49
Trinka (10.3988/jcn.2021.17.1.11_ref38) 2014; 28
Sreenath (10.3988/jcn.2021.17.1.11_ref18) 2010; 14
Holtkamp (10.3988/jcn.2021.17.1.11_ref48) 2005; 76
Shorvon (10.3988/jcn.2021.17.1.11_ref8) 2005; 7
O'Brien (10.3988/jcn.2021.17.1.11_ref34) 1998; 51
Bryant (10.3988/jcn.2021.17.1.11_ref39) 1996; 46
Strzelczyk (10.3988/jcn.2021.17.1.11_ref44) 2017; 58
Silbergleit (10.3988/jcn.2021.17.1.11_ref19) 2012; 366
Glauser (10.3988/jcn.2021.17.1.11_ref22) 2016; 16
Mirrakhimov (10.3988/jcn.2021.17.1.11_ref59) 2015; 2015
Naylor (10.3988/jcn.2021.17.1.11_ref65) 2005; 25
Novy (10.3988/jcn.2021.17.1.11_ref49) 2010; 51
Shorvon (10.3988/jcn.2021.17.1.11_ref12) 2011; 134
Ferlisi (10.3988/jcn.2021.17.1.11_ref60) 2012; 135
Rosati (10.3988/jcn.2021.17.1.11_ref69) 2018; 32
Kapur (10.3988/jcn.2021.17.1.11_ref31) 2019; 381
References_xml – start-page: 21
  volume-title: Status epilepticus: its clinical features and treatment in children and adults
  year: 1994
  ident: 10.3988/jcn.2021.17.1.11_ref5
  doi: 10.1017/CBO9780511526930.003
– volume: 54
  start-page: 502
  year: 2013
  ident: 10.3988/jcn.2021.17.1.11_ref50
  publication-title: Epilepsia
  doi: 10.1111/epi.12064
– volume: 2015
  start-page: 831260
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref70
  publication-title: Crit Care Res Pract
– volume: 14
  start-page: 162
  year: 2010
  ident: 10.3988/jcn.2021.17.1.11_ref18
  publication-title: Eur J Paediatr Neurol
  doi: 10.1016/j.ejpn.2009.02.004
– volume: 102
  start-page: 106675
  year: 2020
  ident: 10.3988/jcn.2021.17.1.11_ref23
  publication-title: Epilepsy Behav
  doi: 10.1016/j.yebeh.2019.106675
– volume: 51
  start-page: 251
  year: 2010
  ident: 10.3988/jcn.2021.17.1.11_ref49
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2009.02323.x
– volume: 135
  start-page: 2314
  year: 2012
  ident: 10.3988/jcn.2021.17.1.11_ref60
  publication-title: Brain
  doi: 10.1093/brain/aws091
– volume: 11
  start-page: 102
  year: 1970
  ident: 10.3988/jcn.2021.17.1.11_ref3
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1157.1970.tb03871.x
– volume: 58
  start-page: 933
  year: 2017
  ident: 10.3988/jcn.2021.17.1.11_ref44
  publication-title: Epilepsia
  doi: 10.1111/epi.13716
– volume: 68
  start-page: 79
  year: 2019
  ident: 10.3988/jcn.2021.17.1.11_ref75
  publication-title: Seizure
  doi: 10.1016/j.seizure.2018.08.004
– volume: 17
  start-page: 3
  year: 2012
  ident: 10.3988/jcn.2021.17.1.11_ref21
  publication-title: Neurocrit Care
  doi: 10.1007/s12028-012-9695-z
– volume: 60
  start-page: 291
  year: 1903
  ident: 10.3988/jcn.2021.17.1.11_ref9
  publication-title: Am J Insanity
– volume: 311
  start-page: 1652
  year: 2014
  ident: 10.3988/jcn.2021.17.1.11_ref20
  publication-title: JAMA
  doi: 10.1001/jama.2014.2625
– volume: 249
  start-page: 1452
  year: 1983
  ident: 10.3988/jcn.2021.17.1.11_ref14
  publication-title: JAMA
  doi: 10.1001/jama.1983.03330350028021
– volume: 381
  start-page: 2103
  year: 2019
  ident: 10.3988/jcn.2021.17.1.11_ref31
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1905795
– volume: 49
  start-page: 340
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref46
  publication-title: Epilepsy Behav
  doi: 10.1016/j.yebeh.2015.06.032
– volume: 43
  start-page: 146
  year: 2002
  ident: 10.3988/jcn.2021.17.1.11_ref61
  publication-title: Epilepsia
  doi: 10.1046/j.1528-1157.2002.28501.x
– volume: 25
  start-page: 7724
  year: 2005
  ident: 10.3988/jcn.2021.17.1.11_ref65
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.4944-04.2005
– volume: 60
  start-page: 645-698-7
  year: 1904
  ident: 10.3988/jcn.2021.17.1.11_ref10
  publication-title: Am J Insanity
– volume: 56
  start-page: 1515
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref1
  publication-title: Epilepsia
  doi: 10.1111/epi.13121
– volume: 51
  start-page: 177
  year: 2010
  ident: 10.3988/jcn.2021.17.1.11_ref72
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2009.02297.x
– volume: 43
  start-page: 1003
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref54
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000000881
– volume: 12
  start-page: 281
  year: 2016
  ident: 10.3988/jcn.2021.17.1.11_ref73
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2016.45
– volume: 68
  start-page: 486
  year: 1992
  ident: 10.3988/jcn.2021.17.1.11_ref57
  publication-title: Br J Anaesth
  doi: 10.1093/bja/68.5.486
– volume: 32
  start-page: 997
  year: 2018
  ident: 10.3988/jcn.2021.17.1.11_ref69
  publication-title: CNS Drugs
  doi: 10.1007/s40263-018-0569-6
– volume: 54
  start-page: 393
  year: 2013
  ident: 10.3988/jcn.2021.17.1.11_ref43
  publication-title: Epilepsia
  doi: 10.1111/epi.12058
– volume: 28
  start-page: 623
  year: 2014
  ident: 10.3988/jcn.2021.17.1.11_ref38
  publication-title: CNS Drugs
  doi: 10.1007/s40263-014-0167-1
– volume: 79
  start-page: 2355
  year: 2012
  ident: 10.3988/jcn.2021.17.1.11_ref67
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e318278b685
– volume: 16
  start-page: 48
  year: 2016
  ident: 10.3988/jcn.2021.17.1.11_ref22
  publication-title: Epilepsy Curr
  doi: 10.5698/1535-7597-16.1.48
– volume: 2014
  start-page: CD003723
  year: 2014
  ident: 10.3988/jcn.2021.17.1.11_ref25
  publication-title: Cochrane Database Syst Rev
– volume: 54
  start-page: 1498
  year: 2013
  ident: 10.3988/jcn.2021.17.1.11_ref68
  publication-title: Epilepsia
  doi: 10.1111/epi.12247
– volume: 7
  start-page: 262
  year: 1991
  ident: 10.3988/jcn.2021.17.1.11_ref33
  publication-title: Pediatr Neurol
  doi: 10.1016/0887-8994(91)90042-J
– volume: 22
  start-page: 489
  year: 1981
  ident: 10.3988/jcn.2021.17.1.11_ref4
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1157.1981.tb06159.x
– volume: 51
  start-page: 1034
  year: 1998
  ident: 10.3988/jcn.2021.17.1.11_ref34
  publication-title: Neurology
  doi: 10.1212/WNL.51.4.1034
– volume: 17
  start-page: 348
  year: 2010
  ident: 10.3988/jcn.2021.17.1.11_ref63
  publication-title: Eur J Neurol
  doi: 10.1111/j.1468-1331.2009.02917.x
– volume: 7
  start-page: 1
  year: 2005
  ident: 10.3988/jcn.2021.17.1.11_ref8
  publication-title: Epileptic Disord
  doi: 10.1684/j.1950-6945.2005.tb00092.x
– volume: 48
  start-page: 478
  year: 2007
  ident: 10.3988/jcn.2021.17.1.11_ref37
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2007.00989.x
– volume: 52 Suppl 8
  start-page: 70
  year: 2011
  ident: 10.3988/jcn.2021.17.1.11_ref76
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2011.03243.x
– volume: 101
  start-page: 106466
  year: 2019
  ident: 10.3988/jcn.2021.17.1.11_ref29
  publication-title: Epilepsy Behav
  doi: 10.1016/j.yebeh.2019.106466
– volume: 15
  start-page: 1113
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref41
  publication-title: Expert Rev Neurother
  doi: 10.1586/14737175.2015.1088785
– volume: 46
  start-page: S17
  year: 1996
  ident: 10.3988/jcn.2021.17.1.11_ref36
  publication-title: Neurology
  doi: 10.1212/WNL.46.6_Suppl_1.17S
– volume: 28
  start-page: 874
  year: 1978
  ident: 10.3988/jcn.2021.17.1.11_ref32
  publication-title: Neurology
  doi: 10.1212/WNL.28.9.874
– volume: 46
  start-page: 465
  year: 1996
  ident: 10.3988/jcn.2021.17.1.11_ref39
  publication-title: Neurology
  doi: 10.1212/WNL.46.2.465
– volume: 59
  start-page: 205
  year: 2002
  ident: 10.3988/jcn.2021.17.1.11_ref47
  publication-title: Arch Neurol
  doi: 10.1001/archneur.59.2.205
– volume: 21
  start-page: 233
  year: 2012
  ident: 10.3988/jcn.2021.17.1.11_ref40
  publication-title: Seizure
  doi: 10.1016/j.seizure.2012.01.008
– volume: 7
  start-page: 5
  year: 2005
  ident: 10.3988/jcn.2021.17.1.11_ref7
  publication-title: Epileptic Disord
  doi: 10.1684/j.1950-6945.2005.tb00093.x
– volume: 1
  start-page: 57
  year: 2011
  ident: 10.3988/jcn.2021.17.1.11_ref2
  publication-title: J Epilepsy Res
  doi: 10.14581/jer.11011
– volume: 82
  start-page: 656
  year: 2014
  ident: 10.3988/jcn.2021.17.1.11_ref53
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000000009
– volume: 51 Suppl 3
  start-page: 106
  year: 2010
  ident: 10.3988/jcn.2021.17.1.11_ref66
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2010.02622.x
– volume: 134
  start-page: 2802
  year: 2011
  ident: 10.3988/jcn.2021.17.1.11_ref12
  publication-title: Brain
  doi: 10.1093/brain/awr215
– start-page: 109
  volume-title: Status epilepticus: mechanism and management
  year: 2006
  ident: 10.3988/jcn.2021.17.1.11_ref71
  doi: 10.7551/mitpress/6456.003.0010
– volume: 339
  start-page: 792
  year: 1998
  ident: 10.3988/jcn.2021.17.1.11_ref16
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199809173391202
– volume: 60
  start-page: 81-108-3
  year: 1904
  ident: 10.3988/jcn.2021.17.1.11_ref11
  publication-title: Am J Insanity
– volume: 82
  start-page: 359
  year: 2014
  ident: 10.3988/jcn.2021.17.1.11_ref56
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000000054
– volume: 2015
  start-page: 260385
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref59
  publication-title: Crit Care Res Pract
– volume: 249
  start-page: 762
  year: 1983
  ident: 10.3988/jcn.2021.17.1.11_ref35
  publication-title: JAMA
  doi: 10.1001/jama.1983.03330300046032
– volume: 116
  start-page: 86
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref74
  publication-title: Epilepsy Res
  doi: 10.1016/j.eplepsyres.2015.07.005
– volume: 70
  start-page: 72
  year: 2013
  ident: 10.3988/jcn.2021.17.1.11_ref52
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2013.578
– volume: 76
  start-page: 534
  year: 2005
  ident: 10.3988/jcn.2021.17.1.11_ref48
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2004.041947
– volume: 31
  start-page: 598
  year: 2018
  ident: 10.3988/jcn.2021.17.1.11_ref64
  publication-title: Acta Med Port
  doi: 10.20344/amp.9679
– volume: 14
  start-page: 95
  year: 2008
  ident: 10.3988/jcn.2021.17.1.11_ref58
  publication-title: CNS Neurosci Ther
  doi: 10.1111/j.1527-3458.2008.00043.x
– volume: 49
  start-page: 1277
  year: 2008
  ident: 10.3988/jcn.2021.17.1.11_ref26
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2007.01478.x
– volume: 75
  start-page: 1499
  year: 2015
  ident: 10.3988/jcn.2021.17.1.11_ref13
  publication-title: Drugs
  doi: 10.1007/s40265-015-0454-2
– volume: 250
  start-page: 134
  year: 1989
  ident: 10.3988/jcn.2021.17.1.11_ref24
  publication-title: J Pharmacol Exp Ther
– volume: 40
  start-page: 2677
  year: 2012
  ident: 10.3988/jcn.2021.17.1.11_ref51
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e3182591ff1
– volume: 37
  start-page: 682
  year: 1995
  ident: 10.3988/jcn.2021.17.1.11_ref15
  publication-title: Dev Med Child Neurol
  doi: 10.1111/j.1469-8749.1995.tb15014.x
– volume: 94
  start-page: 10
  year: 2011
  ident: 10.3988/jcn.2021.17.1.11_ref42
  publication-title: Epilepsy Res
  doi: 10.1016/j.eplepsyres.2010.12.014
– volume: 19
  start-page: 405
  year: 1997
  ident: 10.3988/jcn.2021.17.1.11_ref55
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(97)80126-9
– volume: 345
  start-page: 631
  year: 2001
  ident: 10.3988/jcn.2021.17.1.11_ref17
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa002141
– volume: 42
  start-page: 796
  year: 2001
  ident: 10.3988/jcn.2021.17.1.11_ref6
  publication-title: Epilepsia
  doi: 10.1046/j.1528-1157.2001.10401.x
– volume: 14
  start-page: 4
  year: 2011
  ident: 10.3988/jcn.2021.17.1.11_ref62
  publication-title: Neurocrit Care
  doi: 10.1007/s12028-010-9445-z
– volume: 23
  start-page: 167
  year: 2014
  ident: 10.3988/jcn.2021.17.1.11_ref28
  publication-title: Seizure
  doi: 10.1016/j.seizure.2013.12.007
– volume: 52 Suppl 8
  start-page: 50
  year: 2011
  ident: 10.3988/jcn.2021.17.1.11_ref30
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2011.03237.x
– volume: 366
  start-page: 591
  year: 2012
  ident: 10.3988/jcn.2021.17.1.11_ref19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1107494
– volume: 28
  start-page: 519
  year: 1984
  ident: 10.3988/jcn.2021.17.1.11_ref27
  publication-title: Drugs
  doi: 10.2165/00003495-198428060-00002
– volume: 84
  start-page: 93
  year: 2018
  ident: 10.3988/jcn.2021.17.1.11_ref45
  publication-title: Epilepsy Behav
  doi: 10.1016/j.yebeh.2018.04.025
SSID ssj0067081
Score 2.2779212
SecondaryResourceType review_article
Snippet Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 11
SubjectTerms Review
신경과학
Title Antiepileptic Drug Therapy for Status Epilepticus
URI https://www.ncbi.nlm.nih.gov/pubmed/33480193
https://www.proquest.com/docview/2480279048
https://pubmed.ncbi.nlm.nih.gov/PMC7840311
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002673825
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Clinical Neurology, 2021, 17(1), , pp.11-19
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS8MwFA46QXwR787LqOKLD52NTZvmQUTUocJ8cuBbaG5zKp12K-i_95y1m06G4EtKadIkJ5fzfTnJCSFHLBI6SuLYVwmMJmZE6AudBH6qQJlwF3BjcEG_fR_fdNjdY_T4fTy6EuBgJrXD-6Q6-Wvz4_3zHAb8GTJOAQTuWaMj01PapLwJAXChBdBLMVKxNpvYFGIejK4spRwKBXq3MlrO_MOUkprPcjcLf_7eRvlDL7VWyHIFKL2LsgeskjmbrZHFdmUyXyf0Ihv27BsMfpgctHeVF13voXQl4AFg9RBtFgPvehyjGGyQTuv64fLGr-5J8DULg6HvlOBGJ8KkzAH-czawUNUoDbULrIuFUbFy1KDomeJCK564wAhtNW7j1yrcJLWsn9lt4llt0WUXS1NHmY2jFOCfBdLjUqGMMGGdnIwFI3XlRBzvsniVQCZQlBJEKVGUknIJAa2T40mKt9KBxh9xD0HW8kX3JHq9xme3L19yCdj-VuKZWZif6-Rg3BQShgLaN9LM9ouBPGUJkGwofVInW2XTTLLEA8eAZiE1n2q0SQTMcPpL1nsaudvmwIFDSnf-UZFdsoSv5VLNHqkN88LuA3gZqsaI9DdGPfML3IXsmA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiepileptic+Drug+Therapy+for+Status+Epilepticus&rft.jtitle=Journal+of+clinical+neurology+%28Seoul%2C+Korea%29&rft.au=Kim%2C+Daeyoung&rft.au=Kim%2C+Jae-Moon&rft.au=Cho%2C+Yong+Won&rft.au=Yang%2C+Kwang+Ik&rft.date=2021-01-01&rft.issn=1738-6586&rft.eissn=2005-5013&rft.volume=17&rft.issue=1&rft.spage=11&rft_id=info:doi/10.3988%2Fjcn.2021.17.1.11&rft.externalDBID=n%2Fa&rft.externalDocID=10_3988_jcn_2021_17_1_11
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-6586&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-6586&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-6586&client=summon